Biomarkers of oxidative stress in neurodegenerative diseases

Molecular Basis of Oxidative Stress: Chemistry, Mechanisms, and Disease Pathogenesis

Volumn , Issue , 2013, Pages 359-376

  Sultana, Rukhsana ^a   Cenini, Giovanna ^a   Butterfield, D Allan ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Biomarkers; Carbohydrate oxidation; Lipid peroxidation; Neurodegenerative diseases; Nucleic acid oxidation; Oxidative stress; Protein nitration; Protein oxidation

Indexed keywords

EID: 84961647054     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118355886.ch14     Document Type: Chapter

References (212)

1. Halliwell, B. The wanderings of a free radical. Free Radic. Biol. Med. 2009, 46(5),531-542.
2. Gutteridge, J.M., Halliwell, B. Free radicals and antioxidants in the year 2000. A historical look to the future. Ann. N. Y. Acad. Sci. 2000, 899,136-147.
3. Mayeux, R. Biomarkers: Potential uses and limitations. NeuroRx2004,1(2), 182-188.
4. Atkinson, A.J., Colburn, W.A., DeGruttola, V.G., DeMets, D.L., Downing, G.J., Hoth, D.F., Oates, J.A., Peck, C.C., Schooley, R.T., Spilker, B.A., Woodcock, J., Zeger, S.L. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 2001, 69(3), 89-95.
5. Martin, J.B. Molecular basis of the neurodegenerative disorders. N. Engl. J. Med. 1999,340(25),1970-1980.
6. Love, S. Post mortem sampling of the brain and other tissues in neurodegenerative disease. Histopathology2004, 44(4), 309-317.
7. Markesbery, W.R. Oxidative stress hypothesis in Alzheimer’s disease. Free Radic. Biol. Med. 1997,23(1), 134-147.
8. Halliwell, B. Role of free radicals in the neurodegenerative diseases: Therapeutic implications for antioxidant treatment. Drugs Aging2001,18(9), 685-716.
9. Sayre, L.M., Perry, G., Smith, M.A. Oxidative stress and neurotoxicity. Chem. Res. Toxicol. 2008,21(1), 172-188.
10. Dib, M., Garrel, C., Favier, A., Robin, V., Desnuelle, C. Can malondialdehyde be used as a biological marker of progression in neurodegenerative disease?J. Neurol. 2002,249(4), 367-374.
11. Selkoe, D.J. Alzheimer’s disease: Genes, proteins, and therapy. Physiol. Rev. 2001, 81(2), 741-766.
12. Duyckaerts, C., Delatour, B., Potier, M.C. Classification and basic pathology of Alzheimer’s disease. Acta Neuro-pathol. 2009,118(1),5-36.
13. Poewe, W., Mahlknecht, P. The clinical progression of Parkinson’s disease. Parkinsonism Relat. Disord. 2009, 15(Suppl 4), S28-S32.
14. Lim, S.Y., Lang, A.E. The nonmotor symptoms of Parkinson’s disease—An overview.Mov. Disord. 2010,25(Suppl 1), S123-S130.
15. Leong, S.L., Cappai, R., Barnham, K.J., Pham, C.L. Modulation of alpha-synuclein aggregation by dopamine: A review. Neurochem. Res. 2009,34(10), 1838-1846.
16. Gasser, T. Mendelian forms of Parkinson’s disease. Biochim. Biophys. Acta2009,1792(7), 587-596.
17. Perry, J.J., Shin, D.S., Tainer, J.A. Amyotrophic lateral sclerosis. Adv. Exp. Med. Biol. 2010, 685, 9-20.
18. Hand, C.K., Khoris, J., Salachas, F., Gros-Louis, F., Lopes, A.A., Mayeux-Portas, V., Brewer, C.G., Brown, R.H., Jr., Meininger, V., Camu, W., Rouleau, G.A. A novel locus for familial amyotrophic lateral sclerosis, on chromosome 18q. Am. J. Hum. Genet. 2002, 70(1), 251-256.
19. Dalle-Donne, I., Aldini, G., Carini, M., Colombo, R., Rossi, R., Milzani, A. Protein carbonylation, cellular dysfunction, and disease progression. J. Cell. Mol. Med. 2006, 10(2), 389-406.
20. Butterfield, D.A., Stadtman, E.R. Protein oxidation processes in aging brain. Adv. Cell Aging Gerontol. 1997, 2, 161-191.
21. Balcz, B., Kirchner, L., Cairns, N., Fountoulakis, M., Lubec, G. Increased brain protein levels of carbonyl reductase and alcohol dehydrogenase in Down syndrome and Alzheimer’s disease. J. Neural Transm. Suppl. 2001, 61,193-201.
22. Smith, C.D., Carney, J.M., Starke-Reed, P.E., Oliver, C.N., Stadtman, E.R., Floyd, R.A., Markesbery, W.R. Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 1991, 88(23), 10540-10543.
23. Smith, M.A., Sayre, L.M., Anderson, V.E., Harris, P.L., Beal, M.F., Kowall, N., Perry, G. Cytochemical demonstration of oxidative damage in Alzheimer disease by immunochemical enhancement of the carbonyl reaction with 2,4-dinitrophenylhydrazine. J. Histochem. Cyto-chem. 1998, 46(6), 731-735.
24. Sultana, R., Ravagna, A., Mohmmad-Abdul, H., Calabrese, V., Butterfield, D.A. Ferulic acid ethyl ester protects neurons against amyloid beta- peptide(1-42)-induced oxidative stress and neurotoxicity: Relationship to antioxidant activity. J. Neurochem. 2005, 92(4), 749-758.
25. Hensley, K., Hall, N., Subramaniam, R., Cole, P., Harris, M., Aksenov, M., Aksenova, M., Gabbita, S.P, Wu, J.F., Carney, J.M., et al. Brain regional correspondence between Alzheimer’s disease histopathology and biomarkers of protein oxidation. J. Neurochem. 1995, 65(5), 2146-2156.
26. Bogdanovic, N., Zilmer, M., Zilmer, K., Rehema, A., Karelson, E. The Swedish APP670/671 Alzheimer’s disease mutation: The first evidence for strikingly increased oxidative injury in the temporal inferior cortex. Dement. Geriatr. Cogn. Disord. 2001,12(6), 364-370.
27. Aksenov, M.Y., Aksenova, M.V., Butterfield, D.A., Geddes, J.W., Markesbery, W.R. Protein oxidation in the brain in Alzheimer’s disease. Neuroscience2001,103(2), 373-383.
28. Reed, T., Perluigi, M., Sultana, R., Pierce, W.M., Klein, J.B., Turner, D.M., Coccia, R., Markesbery, W.R., Butterfield, D.A. Redox proteomic identification of 4-hydroxy-2-nonenal-modified brain proteins in amnestic mild cognitive impairment: Insight into the role of lipid peroxidation in the progression and pathogenesis of Alzheimer’s disease. Neurobiol. Dis. 2008, 30(1), 107-120.
29. Butterfield, D.A., Galvan, V., Lange, M.B., Tang, H., Sowell, R.A., Spilman, P, Fombonne, J., Gorostiza, O., Zhang, J., Sultana, R., Bredesen, D.E. In vivo oxidative stress in brain of Alzheimer disease transgenic mice: Requirement for methionine 35 in amyloid beta-peptide of APPFree Radic. Biol. Med. 2010, 48(1), 136-144.
30. Castegna, A., Aksenov, M., Aksenova, M., Thong-boonkerd, V., Klein, J.B., Pierce, W.M., Booze, R., Markesbery, W.R., Butterfield, D.A. Proteomic identification of oxidatively modified proteins in Alzheimer’s disease brain. Part I: Creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radic. Biol. Med. 2002, 33(4), 562-571.
31. Castegna, A., Aksenov, M., Thongboonkerd, V., Klein, J.B., Pierce, W.M., Booze, R., Markesbery, W.R., Butter field, D.A. Proteomic identification of oxidatively modified proteins in Alzheimer’s disease brain. Part II: Dihydropyrimidinase-related protein 2, alpha-enolase and heat shock cognate 71’ J. Neurochem. 2002, 82(6), 1524-1532.
32. Choi, J., Forster, M.J., McDonald, S.R., Weintraub, S.T., Carroll, C.A., Gracy, R.W. Proteomic identification of specific oxidized proteins in ApoE-knockout mice: Relevance to Alzheimer’s disease. Free Radic. Biol. Med. 2004,36(9), 1155-1162.
33. Butterfield, D.A., Reed, T., Newman, S.F., Sultana, R. Roles of amyloid beta-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer’s disease and mild cognitive impairment. Free Radic. Biol. Med.2007, 43(5), 658-677.
34. McGeer, PL., Kamo, H., Harrop, R., McGeer, E.G., Martin, W.R., Pate, B.D., Li, D.K. Comparison of PET, MRI, and CT with pathology in a proven case of Alzheimer’s disease. Neurology1986, 36(12), 1569-1574.
35. Aaronson, R.M., Graven, K.K., Tucci, M., McDonald, R.J., Farber, H.W. Non-neuronal enolase is an endothelial hypoxic stress protein. J. Biol. Chem. 1995,270(46),27752-27757.
36. al-Giery, A.G., Brewer, J.M. Characterization of the interaction of yeast enolase with polynucleotides’Biochim. Biophys. Acta1992,1159(2), 134-140.
37. Subramanian, A., Miller, D.M. Structural analysis of alpha-enolase. Mapping the functional domains involved in down-regulation of the c-myc protooncogene. J. Biol. Chem. 2000,275(8), 5958-5965.
38. Butterfield, D.A., Lange, M.L. Multifunctional roles of enolase in Alzheimer’s disease brain: Beyond altered glucose metabolism. J. Neurochem. 2009, 111(4), 915-933.
39. Butterfield, D.A., Abdul, H.M., Opii, W., Newman, S.F., Joshi, G., Ansari, M.A., Sultana, R. Pin1 in Alzheimer’s disease. J. Neurochem. 2006, 98(6), 1697-1706.
40. Pastorino, L., Sun, A., Lu, PJ., Zhou, X.Z., Balastik, M., Finn, G., Wulf, G., Lim, J., Li, S.H., Li, X., Xia, W., Nicholson, L.K., Lu, K.P. The prolyl isomerase Pin1 regulates amyloid precursor protein processing and amyloid-beta production. Nature2006, 440(7083), 528-534.
41. Sultana, R., Robinson, R.A., Di Domenico, F., Abdul, H.M., Clair, D.K., Markesbery, W.R., Cai, J., Pierce, W.M., Butterfield, D.A. Proteomic identification of specifically carbonylated brain proteins in APP(NLh)/APP(NLh) xPS-1(P264L)/PS-1(P264L) human double mutant knock-in mice model of Alzheimer disease as a function of age. J. Proteomics2011, 74, 2430-2440.
42. Keller, J.N., Schmitt, F.A., Scheff, S.W., Ding, Q., Chen, Q., Butterfield, D.A., Markesbery, W.R. Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology2005, 64(7), 1152-1156.
43. Butterfield, D.A., Poon, H.F., St Clair, D., Keller, J.N., Pierce, W.M., Klein, J.B., Markesbery, W.R. Redox pro-teomics identification of oxidatively modified hippocampal proteins in mild cognitive impairment: Insights into the development of Alzheimer’s disease. Neurobiol. Dis. 2006,22(2), 223-232.
44. Sultana, R., Perluigi, M., Newman, S.F., Pierce, W.M., Cini, C., Coccia, R., Butterfield, A. Redox proteomic analysis of carbonylated brain proteins in mild cognitive impairment and early Alzheimer’s disease. Antioxid. Redox Signal. 2009. doi: 10.1089/ars.2009.2810.
45. Winklhofer, K.F., Haass, C. Mitochondrial dysfunction in Parkinson’s disease. Biochim. Biophys. Acta2010, 1802(1),29-44.
46. Floor, E., Wetzel, M.G. Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay. J. Neuro-chem. 1998, 70(1), 268-275.
47. Watfa, G., Dragonas, C., Brosche, T., Dittrich, R., Sieber, C.C., Alecu, C., Benetos, A., Nzietchueng, R. Study of telomere length and different markers of oxidative stress in patients with Parkinson’s disease. J. Nutr. Health Aging2011,15(4), 277-281.
48. Asanuma, M., Miyazaki, I., Diaz-Corrales, F.J., Miyoshi, K., Ogawa, N., Murata, M. Preventing effects of a novel anti-Parkinsonian agent zonisamide on dopamine quinone formation. Neurosci. Res. 2008, 60(1), 106-113.
49. Chinta, S.J., Rajagopalan, S., Butterfield, D.A., Andersen, J.K. In vitro and in vivo neuroprotection by gamma-glutamylcysteine ethyl ester against MPTP: Relevance to the role of glutathione in Parkinson’s disease. Neurosci. Lett. 2006, 402(1-2), 137-141.
50. De Iuliis, A., Grigoletto, J., Recchia, A., Giusti, P, Arslan, P. A proteomic approach in the study of an animal model of Parkinson’s disease. Clin. Chim. Acta2005, 357(2), 202-209.
51. Poon, H.F., Frasier, M., Shreve, N., Calabrese, V., Wolozin, B., Butterfield, D.A. Mitochondrial associated metabolic proteins are selectively oxidized in A30P alpha-synuclein transgenic mice—A model of familial Parkinson’s disease. Neurobiol. Dis. 2005,18(3), 492-498.
52. Barber, S.C., Shaw, PJ. Oxidative stress in ALS: Key role in motor neuron injury and therapeutic target. Free Radic. Biol. Med. 2010, 48(5), 629-641.
53. Shaw, P.J., Ince, PG., Falkous, G., Mantle, D. Oxidative damage to protein in sporadic motor neuron disease spinal cord. Ann. Neurol. 1995,38(4), 691-695.
54. Ferrante, R.J., Browne, S.E., Shinobu, L.A., Bowling, A.C., Baik, M.J., MacGarvey, U., Kowall, N.W., Brown, R.H., Jr., Beal, M.F. Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J. Neurochem. 1997, 69(5), 2064-2074.
55. Bowling, A.C., Schulz, J.B., Brown, R.H., Jr., Beal, M.F. Superoxide dismutase activity, oxidative damage, and mitochondrial energy metabolism in familial and sporadic amyotrophic lateral sclerosis. J. Neurochem. 1993, 61(6), 2322-2325.
56. Lyras, L., Evans, PJ., Shaw, PJ., Ince, PG., Halliwell, B. Oxidative damage and motor neurone disease difficulties in the measurement of protein carbonyls in human brain tissue. Free Radic. Res. 1996,24(5), 397-406.
57. Poon, H.F., Hensley, K., Thongboonkerd, V., Merchant, M.L., Lynn, B.C., Pierce, W.M., Klein, J.B., Calabrese, V., Butterfield, D.A. Redox proteomics analysis of oxidatively modified proteins in G93A-SOD1 transgenic mice—A model of familial amyotrophic lateral sclerosis. Free Radic. Biol. Med. 2005, 39(4), 453-462.
58. Smith, M.A., Richey Harris, PL., Sayre, L.M., Beckman, J.S., Perry, G. Widespread peroxynitrite-mediated damage in Alzheimer’s disease. J. Neurosci. 1997, 17(8), 2653-2657.
59. Williamson, K.S., Gabbita, S.P, Mou, S., West, M., Pye, Q.N., Markesbery, W.R., Cooney, R.V., Grammas, P, Reimann-Philipp, U., Floyd, R.A., Hensley, K. The nitration product 5-nitro-gamma-tocopherol is increased in the Alzheimer brain. Nitric Oxide2002, 6(2), 221-227.
60. Fernandez-Vizarra, P, Fernandez, A.P., Castro-Blanco, S., Encinas, J.M., Serrano, J., Bentura, M.L., Munoz, P, Martinez-Murillo, R., Rodrigo, J. Expression of nitric oxide system in clinically evaluated cases of Alzheimer’s disease. Neurobiol. Dis. 2004,15(2), 287-305.
61. Hensley, K., Maidt, M.L., Yu, Z., Sang, H., Markesbery, W.R., Floyd, R.A. Electrochemical analysis of protein nitrotyrosine and dityrosine in the Alzheimer brain indicates region-specific accumulation. J. Neurosci. 1998, 13(20), 8126-8132.
62. Horiguchi, T., Uryu, K., Giasson, B.I., Ischiropoulos, H., LightFoot, R., Bellmann, C., Richter-Landsberg, C., Lee, V.M., Trojanowski, J.Q. Nitration of tau protein is linked to neurodegeneration in tauopathies. Am. J. Pathol. 2003, 163(3), 1021-1031.
63. Zhang, Y.J., Xu, Y.F., Liu, Y.H., Yin, J., Li, H.L., Wang, Q., Wang, J.Z. Peroxynitrite induces Alzheimer-like tau modifications and accumulation in rat brain and its underlying mechanisms. FASEB J. 2006, 20(9), 1431-1442.
64. Berlett, B.S., Friguet, B., Yim, M.B., Chock, PB., Stadt-man, E.R. Peroxynitrite-mediated nitration of tyrosine residues in Escherichia coli glutamine synthetase mimics adenylylation: Relevance to signal transduction. Proc. Natl. Acad. Sci. U.S.A. 1996, 93(5), 1776-1780.
65. Yi, D., Perkins, P.D. Identification of ubiquitin nitration and oxidation using a liquid chromatography/mass selective detector system. J. Biomol. Tech. 2005,16(4), 364-370.
66. Anantharaman, M., Tangpong, J., Keller, J.N., Murphy, M.P, Markesbery, W.R., Kiningham, K.K., St Clair, D.K. Beta-amyloid mediated nitration of manganese superoxide dismutase: Implication for oxidative stress in a APPNLH/NLH X PS-1P264L/P264L double knock-in mouse model of Alzheimer’s disease. Am. J. Pathol. 2006, 168(5),1608-1618.
67. Yamakura, F., Taka, H., Fujimura, T., Murayama, K. Inactivation of human manganese-superoxide dismutase by peroxynitrite is caused by exclusive nitration of tyrosine 34 to 3-nitrotyrosine. J. Biol. Chem. 1998,273(23), 14085-14089.
68. Castegna, A., Thongboonkerd, V., Klein, J.B., Lynn, B., Markesbery, W.R., Butterfield, D.A. Proteomic identification of nitrated proteins in Alzheimer’s disease brain. J. Neurochem. 2003, 85(6), 1394-1401.
69. Sultana, R., Poon, H.F., Cai, J., Pierce, W.M., Merchant, M., Klein, J.B., Markesbery, W.R., Butterfield, D.A. Identification of nitrated proteins in Alzheimer’s disease brain using a redox proteomics approach. Neurobiol. Dis. 2006,22(1), 76-87.
70. Guix, F.X., Ill-Raga, G., Bravo, R., Nakaya, T., de Fabritiis, G., Coma, M., Miscione, G.P, Villa-Freixa, J., Suzuki, T., Fernandez-Busquets, X., Valverde, M.A., de Strooper, B., Munoz, F.J. Amyloid-dependent triosephosphate isomer-ase nitrotyrosination induces glycation and tau fibrillation. Brain2009,132(Pt 5), 1335-1345.
71. Reyes, J.F., Reynolds, M.R., Horowitz, PM., Fu, Y., Guillozet-Bongaarts, A.L., Berry, R., Binder, L.I. A possible link between astrocyte activation and tau nitration in Alzheimer’s disease. Neurobiol. Dis. 2008, 31(2), 198-208.
72. Baxi, M.D., Vishwanatha, J.K. Uracil DNA-glycosylase/glyceraldehyde-3-phosphate dehydrogenase is an Ap4A binding protein. Biochemistry1995, 34(30), 9700-9707.
73. Zheng, L., Roeder, R.G., Luo, Y. S phase activation of the histone H2B promoter by OCA-S, a coactivator complex that contains GAPDH as a key component. Cell2003, 114(2), 255-266.
74. Launay, J.F., Jellali, A., Vanier, M.T. Glyceraldehyde-3-phosphate dehydrogenase is a microtubule binding protein in a human colon tumor cell line. Biochim. Biophys. Acta1989, 996(1-2), 103-109.
75. Patterson, R.L., van Rossum, D.B., Kaplin, A.I., Barrow, R.K., Snyder, S.H. Inositol 1,4,5-trisphosphate receptor/GAPDH complex augments Ca2+ release via locally derived NADH. Proc. Natl. Acad. Sci. U.S.A. 2005,102(5), 1357-1359.
76. Puder, M., Soberman, R.J. Glutathione conjugates recognize the Rossmann fold of glyceraldehyde-3-phosphate dehydrogenase. J. Biol. Chem. 1997, 272(16), 10936-10940.
77. Butterfield, D.A., Reed, T.T., Perluigi, M., De Marco, C., Coccia, R., Keller, J.N., Markesbery, W.R., Sultana, R. Elevated levels of 3-nitrotyrosine in brain from subjects with amnestic mild cognitive impairment: Implications for the role of nitration in the progression of Alzheimer’s disease. Brain Res. 2007,1148, 243-248.
78. Sultana, R., Reed, T., Perluigi, M., Coccia, R., Pierce, W.M., Butterfield, D.A. Proteomic identification of nitrated brain proteins in amnestic mild cognitive impairment: A regional study. J. Cell. Mol. Med. 2007,11(4), 839-851.
79. Jenner, P, Dexter, D.T., Sian, J., Schapira, A.H., Marsden, C.D. Oxidative stress as a cause of nigral cell death in Parkinson’s disease and incidental Lewy body disease. The Royal Kings and Queens Parkinson’s Disease Research Group. Ann. Neurol. 1992, 32(Suppl.), S82-S87.
80. Giasson, B.I., Duda, J.E., Murray, I.V., Chen, Q., Souza, J.M., Hurtig, H.I., Ischiropoulos, H., Trojanowski, J.Q., Lee, V.M. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucle-inopathy lesions. Science2000,290(5493), 985-989.
81. Yu, Z., Xu, X., Xiang, Z., Zhou, J., Zhang, Z., Hu, C., He, C. Nitrated alpha-synuclein induces the loss of dopaminergic neurons in the substantia nigra of rats. PLoS ONE2010,5(4), e9956.
82. Chinta, S. J., Andersen, J.K. Nitrosylation and nitration of mitochondrial complex I in Parkinson’s disease. Free Radic. Res. 2011, 45(1), 53-58.
83. Mythri, R.B., Jagatha, B., Pradhan, N., Andersen, J., Bharath, M.M. Mitochondrial complex I inhibition in Parkinson’s disease: How can curcumin protect mitochondria? Antioxid. Redox Signal. 2007, 9(3), 399-408.
84. Abe, K., Pan, L.H., Watanabe, M., Konno, H., Kato, T., Itoyama, Y. Upregulation of protein-tyrosine nitration in the anterior horn cells of amyotrophic lateral sclerosis. Neurol. Res. 1997,19(2), 124-128.
85. Uchida, K. 4-Hydroxy-2-nonenal: A product and mediator of oxidative stress. Prog. Lipid Res. 2003, 42(4), 318-343.
86. Cracowski, J.L., Durand, T., Bessard, G. Isoprostanes as a biomarker of lipid peroxidation in humans: Physiology, pharmacology and clinical implications. Trends Pharmacol. Sci. 2002,23(8), 360-366.
87. Subramaniam, R., Roediger, F., Jordan, B., Mattson, M.P, Keller, J.N., Waeg, G., Butterfield, D.A. The lipid peroxidation product, 4-hydroxy-2-trans-nonenal, alters the conformation of cortical synaptosomal membrane proteins. J. Neurochem.1997, 69(3), 1161-1169.
88. Halliwell, B. Lipid peroxidation, antioxidants and cardiovascular disease: How should we move forward? Cardio-vasc. Res. 2000, 47(3), 410-418.
89. Uchida, K. Role of reactive aldehyde in cardiovascular diseases. Free Radic. Biol. Med. 2000,28(12), 1685-1696.
90. Sayre, L.M., Smith, M.A., Perry, G. Chemistry and biochemistry of oxidative stress in neurodegenerative disease. Curr. Med. Chem. 2001, 8(7), 721-738.
91. Butterfield, D. A., Bader Lange, M.L., Sultana, R. Involvements of the lipid peroxidation product, HNE, in the pathogenesis and progression of Alzheimer’s disease. Biochim. Biophys. Acta2010,1801(8), 924-929.
92. Irizarry, M.C., Yao, Y., Hyman, B.T., Growdon, J.H., Pratico, D. Plasma F2A isoprostane levels in Alzheimer’s and Parkinson’s disease. Neurodegener Dis. 2007, 4(6), 403-405.
93. Markesbery, W.R., Kryscio, R.J., Lovell, M.A., Morrow, J.D. Lipid peroxidation is an early event in the brain in amnestic mild cognitive impairment. Ann. Neurol. 2005, 58(5), 730-735.
94. Yao, Y., Zhukareva, V., Sung, S., Clark, C.M., Rokach, J., Lee, V.M., Trojanowski, J.Q., Pratico, D. Enhanced brain levels of 8,12-iso-iPF2alpha-VI differentiate AD from frontotemporal dementia. Neurology2003, 61(4),475-478.
95. Volkel, W., Sicilia, T., Pahler, A., Gsell, W., Tatschner, T., Jellinger, K., Leblhuber, F., Riederer, P., Lutz, W.K., Gotz, M.E. Increased brain levels of 4-hydroxy-2-nonenal glutathione conjugates in severe Alzheimer’s disease. Neu-rochem. Int.2006, 48(8),679-686.
96. Lovell, M.A., Xie, C., Markesbery, W.R. Decreased glutathione transferase activity in brain and ventricular fluid in Alzheimer’s disease. Neurology1998, 51(6), 1562-1566.
97. Sultana, R., Butterfield, D.A. Oxidatively modified GST and MRP1 in Alzheimer’s disease brain: Implications for accumulation of reactive lipid peroxidation products. Neurochem. Res. 2004,29(12), 2215-2220.
98. Cecarini, V., Ding, Q., Keller, J.N. Oxidative inactivation of the proteasome in Alzheimer’s disease. Free Radic. Res. 2007, 41(6), 673-680.
99. Lovell, M.A., Ehmann, W.D., Mattson, M.P., Markesbery, W.R. Elevated 4-hydroxynonenal in ventricular fluid in Alzheimer’s disease. Neurobiol. Aging1997,18(5), 457-461.
100. Markesbery, W.R., Lovell, M.A. Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer’s disease. Neurobiol. Aging1998, 19(1), 33-36.
101. Zarkovic, K. 4-Hydroxynonenal and neurodegenerative diseases. Mol. Aspects Med. 2003,24(4-5), 293-303.
102. McGrath, L.T., McGleenon, B.M., Brennan, S., McColl, D., Mc, I.S., Passmore, A.P. Increased oxidative stress in Alzheimer’s disease as assessed with 4-hydroxynonenal but not malondialdehyde. QJM2001, 94(9), 485-490.
103. Selley, M.L., Close, D.R., Stern, S.E. The effect of increased concentrations of homocysteine on the concentration of (E)-4-hydroxy-2-nonenal in the plasma and cerebrospinal fluid of patients with Alzheimer’s disease. Neurobiol. Aging 2002,23(3),383-388.
104. Perluigi, M., Sultana, R., Cenini, G., Di Domenico, F., Memo, M., Pierce, W.M., Coccia, R., Butterfield, D.A. Redox proteomics identification of 4-hydroxynonenal-modified brain proteins in Alzheimer’ s disease: Role of lipid peroxidation in Alzheimer’ s disease pathogenesis. Proteomics Clin. Appl. 2009, 3(6), 682-693.
105. Castellani, R.J., Perry, G., Siedlak, S.L., Nunomura, A., Shimohama, S., Zhang, J., Montine, T., Sayre, L.M., Smith, M.A. Hydroxynonenal adducts indicate a role for lipid peroxidation in neocortical and brainstem Lewy bodies in humans. Neurosci. Lett. 2002, 319(1), 25-28.
106. Yoritaka, A., Hattori, N., Uchida, K., Tanaka, M., Stadt-man, E.R., Mizuno, Y. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc. Natl. Acad. Sci. U.S.A. 1996, 93(7), 2696-2701.
107. Morel, P, Tallineau, C., Pontcharraud, R., Piriou, A., Huguet, F. Effects of 4-hydroxynonenal, a lipid peroxidation product, on dopamine transport and Na+/K+ ATPase in rat striatal synaptosomes. Neurochem. Int. 1998,33(6), 531-540.
108. Selley, M.L. (E)-4-hydroxy-2-nonenal may be involved in the pathogenesis of Parkinson’s disease. Free Radic. Biol. Med. 1998,25(2), 169-174.
109. Pedersen, W.A., Fu, W., Keller, J.N., Markesbery, W.R., Appel, S., Smith, R.G., Kasarskis, E., Mattson, M.P. Protein modification by the lipid peroxidation product 4-hydroxynonenal in the spinal cords of amyotrophic lateral sclerosis patients. Ann. Neurol. 1998, 44(5), 819-824.
110. Simpson, E.P, Henry, Y.K., Henkel, J.S., Smith, R.G., Appel, S.H. Increased lipid peroxidation in sera of ALS patients: A potential biomarker of disease burden. Neurology2004,62(10), 1758-1765.
111. Smith, R.G., Henry, Y.K., Mattson, M.P., Appel, S.H. Presence of 4-hydroxynonenal in cerebrospinal fluid of patients with sporadic amyotrophic lateral sclerosis. Ann. Neurol. 1998, 44(4), 696-699.
112. Perluigi, M., Fai Poon, H., Hensley, K., Pierce, W.M., Klein, J.B., Calabrese, V., De Marco, C., Butterfield, D.A. Proteomic analysis of 4-hydroxy-2-nonenal-modified proteins in G93A-SOD1 transgenic mice—A model of familial amyotrophic lateral sclerosis. Free Radic. Biol. Med. 2005,38(7), 960-968.
113. Ryberg, H., An, J., Darko, S., Lustgarten, J.L., Jaffa, M., Gopalakrishnan, V., Lacomis, D., Cudkowicz, M., Bowser, R. Discovery and verification of amyotrophic lateral sclerosis biomarkers by proteomics. Muscle Nerve2010, 42(1), 104-111.
114. Bowser, R., Lacomis, D. Applying proteomics to the diagnosis and treatment of ALS and related diseases. Muscle Nerve2009, 40(5),753-762.
115. Pasinetti, G.M., Ungar, L.H., Lange, D.J., Yemul, S., Deng, H., Yuan, X., Brown, R.H., Cudkowicz, M.E., Newhall, K., Peskind, E., Marcus, S., Ho, L. Identification of potential CSF biomarkers in ALS. Neurology2006, 66(8), 1218-1222.
116. Martin-Aragon, S., Bermejo-Bescos, P, Benedi, J., Felici, E., Gil, P, Ribera, J.M., Villar, A.M. Metalloproteinase’s activity and oxidative stress in mild cognitive impairment and Alzheimer’s disease. Neurochem. Res. 2009, 34(2), 373-378.
117. Polidori, M.C., Mecocci, P. Plasma susceptibility to free radical-induced antioxidant consumption and lipid peroxidation is increased in very old subjects with Alzheimer disease. J. Alzheimers Dis. 2002, 4(6), 517-522.
118. Bourdel-Marchasson, I., Delmas-Beauvieux, M.C., Peu-chant, E., Richard-Harston, S., Decamps, A., Reignier, B., Emeriau, J.P, Rainfray, M. Antioxidant defences and oxidative stress markers in erythrocytes and plasma from normally nourished elderly Alzheimer patients. Age. Ageing2001, 30(3), 235-241.
119. Padurariu, M., Ciobica, A., Hritcu, L., Stoica, B., Bild, W., Stefanescu, C. Changes of some oxidative stress markers in the serum of patients with mild cognitive impairment and Alzheimer’s disease. Neurosci. Lett. 2010, 469(1), 6-10.
120. Casado, A., Encarnación Lopez-Fernandez, M., Concepcion Casado, M., de La Torre, R. Lipid peroxidation and antioxidant enzyme activities in vascular and Alzheimer dementias. Neurochem. Res. 2008, 33(3), 450-458.
121. Dei, R., Takeda, A., Niwa, H., Li, M., Nakagomi, Y., Wata-nabe, M., Inagaki, T., Washimi, Y., Yasuda, Y., Horie, K., Miyata, T., Sobue, G. Lipid peroxidation and advanced glycation end products in the brain in normal aging and in Alzheimer’s disease. Acta Neuropathol. 2002,104(2), 113-122.
122. Dalfo, E., Ferrer, I. Early alpha-synuclein lipoxidation in neocortex in Lewy body diseases. Neurobiol. Aging2008, 29(3), 408-417.
123. Dalfo, E., Portero-Otin, M., Ayala, V., Martinez, A., Pamplona, R., Ferrer, I. Evidence of oxidative stress in the neocortex in incidental Lewy body disease. J. Neuro-pathol. Exp. Neurol. 2005, 64(9), 816-830.
124. Dexter, D.T., Carter, C.J., Wells, F.R., Javoy-Agid, F., Agid, Y., Lees, A., Jenner, P, Marsden, C.D. Basal lipid peroxidation in substantia nigra is increased in Parkinson’s disease. J. Neurochem. 1989,52(2), 381-389.
125. Ilic, T., Jovanovic, M., Jovicic, A., Tomovic, M. Oxidative stress and Parkinson’s disease. Vojnosanit. Pregl. 1998, 55(5), 463-468.
126. Chen, C.M., Liu, J.L., Wu, Y.R., Chen, Y.C., Cheng, H.S., Cheng, M.L., Chiu, D.T. Increased oxidative damage in peripheral blood correlates with severity of Parkinson’s disease. Neurobiol. Dis. 2009, 33(3), 429-435.
127. Younes-Mhenni, S., Frih-Ayed, M., Kerkeni, A., Bost, M., Chazot, G. Peripheral blood markers of oxidative stress in Parkinson’s disease. Eur. Neurol. 2007,58(2), 78-83.
128. Navarro, A., Boveris, A., Bandez, M.J., Sanchez-Pino, M.J., Gomez, C., Muntane, G., Ferrer, I. Human brain cortex: Mitochondrial oxidative damage and adaptive response in Parkinson disease and in dementia with Lewy bodies. Free Radic. Biol. Med. 2009, 46(12), 1574-1580.
129. Sanyal, J., Bandyopadhyay, S.K., Banerjee, T.K., Mukherjee, S.C., Chakraborty, D.P., Ray, B.C., Rao, V.R. Plasma levels of lipid peroxides in patients with Parkinson’s disease. Eur. Rev. Med. Pharmacol. Sci. 2009, 13(2), 129-132.
130. Hall, E.D., Andrus, PK., Oostveen, J.A., Fleck, T.J., Gurney, M.E. Relationship of oxygen radical-induced lipid peroxidative damage to disease onset and progression in a transgenic model of familial ALS. J. Neurosci. Res. 1998,53(1), 66-77.
131. Mahoney, D.J., Kaczor, J.J., Bourgeois, J., Yasuda, N., Tarnopolsky, M.A. Oxidative stress and antioxidant enzyme upregulation in SOD1-G93A mouse skeletal muscle. Muscle Nerve2006, 33(6), 809-816.
132. Oteiza, PI., Uchitel, O.D., Carrasquedo, F., Dubrovski, A.L., Roma, J.C., Fraga, C.G. Evaluation of antioxidants, protein, and lipid oxidation products in blood from sporadic amyotrophic lateral sclerosis patients. Neurochem. Res. 1997,22(4), 535-539.
133. Bonnefont-Rousselot, D., Lacomblez, L., Jaudon, M., Lepage, S., Salachas, F., Bensimon, G., Bizard, C., Doppler, V., Delattre, J., Meininger, V. Blood oxidative stress in amyotrophic lateral sclerosis. J. Neurol. Sci. 2000,178(1), 57-62.
134. Baillet, A., Chanteperdrix, V., Trocme, C., Casez, P, Garrel, C., Besson, G.The role of oxidative stress in amyotrophic lateral sclerosis and Parkinson’s disease. Neurochem. Res. 2010,35,1530-1537.
135. Liu, X., Lovell, M.A., Lynn, B.C. Development of a method for quantification of acrolein-deoxyguanosine adducts in DNA using isotope dilution-capillary LC/MS/MS and its application to human brain tissue. Anal. Chem. 2005, 77(18), 5982-5989.
136. Shamoto-Nagai, M., Maruyama, W., Hashizume, Y., Yoshida, M., Osawa, T., Riederer, P, Naoi, M. In Parkinsonian substantia nigra, alpha-synuclein is modified by acrolein, a lipid-peroxidation product, and accumulates in the dopamine neurons with inhibition of proteasome activity. J. Neural Transm. 2007,114(12), 1559-1567.
137. Shibata, N., Nagai, R., Miyata, S., Jono, T., Horiuchi, S., Hirano, A., Kato, S., Sasaki, S., Asayama, K., Kobayashi, M. Nonoxidative protein glycation is implicated in familial amyotrophic lateral sclerosis with superoxide dismutase-1 mutation. Acta Neuropathol. 2000, 100(3), 275-284.
138. Quinn, J.F., Montine, K.S., Moore, M., Morrow, J.D., Kaye, J.A., Montine, TJ. Suppression of longitudinal increase in CSF F2-isoprostanes in Alzheimer’s disease. J. Alzheimers Dis. 2004, 6(1), 93-97.
139. Pratico, D., Sung, S. Lipid peroxidation and oxidative imbalance: Early functional events in Alzheimer’s disease. J. Alzheimers Dis. 2004, 6(2), 171-175.
140. Montine, T.J., Quinn, J., Kaye, J., Morrow, J.D. F(2)-iso-prostanes as biomarkers of late-onset Alzheimer’s disease. J. Mol. Neurosci. 2007, 33(1), 114-119.
141. Pratico, D., Clark, C.M., Liun, F., Rokach, J., Lee, V.Y., Trojanowski, J.Q. Increase of brain oxidative stress in mild cognitive impairment: A possible predictor of Alzheimer disease. Arch. Neurol. 2002,59(6), 972-976.
142. Butterfield, D.A., Reed, T., Perluigi, M., De Marco, C., Coccia, R., Cini, C., Sultana, R. Elevated protein-bound levels of the lipid peroxidation product, 4-hydroxy-2-nonenal, in brain from persons with mild cognitive impairment. Neurosci. Lett. 2006, 397(3), 170-173.
143. Pratico, D., Clark, C.M., Lee, V.M., Trojanowski, J.Q., Rokach, J., FitzGerald, G. A. Increased 8,12-iso-iPF2alpha-VI in Alzheimer’s disease: Correlation of a noninvasive index of lipid peroxidation with disease severity. Ann. Neurol. 2000, 48(5), 809-812.
144. Montine, T.J., Quinn, J.F., Milatovic, D., Silbert, L.C., Dang, T., Sanchez, S., Terry, E., Roberts, L.J., II, Kaye, J.A., Morrow, J.D. Peripheral F2-isoprostanes and F4-neuroprostanes are not increased in Alzheimer’s disease. Ann. Neurol.2002,52(2), 175-179.
145. Fessel, J.P., Hulette, C., Powell, S., Roberts, L.J., II, Zhang, J. Isofurans, but not F2-isoprostanes, are increased in the substantia nigra of patients with Parkinson’s disease and with dementia with Lewy body disease. J. Neurochem. 2003, 85(3),645-650.
146. Connolly, J., Siderowf, A., Clark, C.M., Mu, D., Pratico, D. F2 isoprostane levels in plasma and urine do not support increased lipid peroxidation in cognitively impaired Parkinson disease patients. Cogn. Behav. Neurol. 2008,21(2), 83-86.
147. Seet, R.C., Lee, C.Y., Lim, E.C., Tan, J.J., Quek, A.M., Chong, W.L., Looi, W.F., Huang, S.H., Wang, H., Chan, Y.H., Halliwell, B. Oxidative damage in Parkinson disease: Measurement using accurate biomarkers. Free Radic. Biol. Med. 2010, 48(4),560-566.
148. Bucala, R., Cerami, A. Advanced glycosylation: Chemistry, biology, and implications for diabetes and aging. Adv. Pharmacol. 1992,23,1-34.
149. Ahmed, N. Advanced glycation endproducts: Role in pathology of diabetic complications. Diabetes Res. Clin. Pract. 2005, 67(1), 3-21.
150. Yan, S.D., Yan, S.F., Chen, X., Fu, J., Chen, M., Kuppusamy, P, Smith, M.A., Perry, G., Godman, G.C., Nawroth, P, et al. Non-enzymatically glycated tau in Alzheimer’s disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid beta-peptide. Nat. Med. 1995,1(7), 693-699.
151. Ledesma, M.D., Bonay, P, Colaco, C., Avila, J. Analysis of microtubule-associated protein tau glycation in paired helical filaments. J. Biol. Chem. 1994, 269(34), 21614-21619.
152. Smith, M.A., Taneda, S., Richey, PL., Miyata, S., Yan, S.D., Stern, D., Sayre, L.M., Monnier, V.M., Perry, G. Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc. Natl. Acad. Sci. U.S.A. 1994, 91(12), 5710-5714.
153. Liu, B.F., Miyata, S., Hirota, Y., Higo, S., Miyazaki, H., Fukunaga, M., Hamada, Y., Ueyama, S., Muramoto, O., Uriuhara, A., Kasuga, M. Methylglyoxal induces apoptosis through activation of p38 mitogen-activated protein kinase in rat mesangial cells. Kidney Int. 2003, 63(3), 947-957.
154. Zhu, X., Rottkamp, C.A., Boux, H., Takeda, A., Perry, G., Smith, M.A. Activation of p38 kinase links tau phosphorylation, oxidative stress, and cell cycle-related events in Alzheimer disease. J. Neuropathol. Exp. Neurol. 2000, 59(10), 880-888.
155. Chen, K., Maley, J., Yu, P.H. Potential implications of endogenous aldehydes in beta-amyloid misfolding, oligomerization and fibrillogenesis. J. Neurochem. 2006,99(5), 1413-1424.
156. Mattson, M.P, Carney, J.W., Butterfield, D.A. A tombstone in Alzheimer’s? Nature1995,373(6514), 481.
157. Takeda, A., Smith, M.A., Avila, J., Nunomura, A., Siedlak, S.L., Zhu, X., Perry, G., Sayre, L.M. In Alzheimer’s disease, heme oxygenase is coincident with Alz50, an epitope of tau induced by 4-hydroxy-2-nonenal modification. J. Neurochem. 2000, 75(3), 1234-1241.
158. Luth, H.J., Ogunlade, V., Kuhla, B., Kientsch-Engel, R., Stahl, P., Webster, J., Arendt, T., Munch, G. Age- and stage-dependent accumulation of advanced glycation end products in intracellular deposits in normal and Alzheimer’s disease brains. Cereb. Cortex2005,15(2), 211-220.
159. Takeuchi, M., Sato, T., Takino, J., Kobayashi, Y., Furuno, S., Kikuchi, S., Yamagishi, S. Diagnostic utility of serum or cerebrospinal fluid levels of toxic advanced glycation end-products (TAGE) in early detection of Alzheimer’s disease. Med. Hypotheses2007, 69(6), 1358-1366.
160. Shuvaev, V.V., Laffont, I., Serot, J.M., Fujii, J., Taniguchi, N., Siest, G. Increased protein glycation in cerebrospinal fluid of Alzheimer’s disease. Neurobiol. Aging2001, 22(3), 397-402.
161. Yan, S.D., Chen, X., Fu, J., Chen, M., Zhu, H., Roher, A., Slattery, T., Zhao, L., Nagashima, M., Morser, J., Migheli, A., Nawroth, P, Stern, D., Schmidt, A.M. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer’s disease. Nature 1996,382(6593), 685-691.
162. Lue, L.F., Yan, S.D., Stern, D.M., Walker, D.G. Preventing activation of receptor for advanced glycation end products in Alzheimer’s disease. Curr. Drug Targets CNS Neurol. Disord. 2005, 4(3), 249-266.
163. Arancio, O., Zhang, H.P., Chen, X., Lin, C., Trinchese, F., Puzzo, D., Liu, S., Hegde, A., Yan, S.F., Stern, A., Luddy, J.S., Lue, L.F., Walker, D. G., Roher, A., Buttini, M., Mucke, L., Li, W., Schmidt, A.M., Kindy, M., Hyslop, PA., Stern, D.M., Du Yan, S.S. RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice. EMBO J. 2004,23(20), 4096-4105.
164. Thome, J., Munch, G., Muller, R., Schinzel, R., Kornhuber, J., Blum-Degen, D., Sitzmann, L., Rosler, M., Heidland, A., Riederer, P. Advanced glycation end products-associated parameters in the peripheral blood of patients with Alzheimer’s disease. Life Sci. 1996,59(8), 679-685.
165. Emanuele, E., D’Angelo, A., Tomaino, C., Binetti, G., Ghidoni, R., Politi, P, Bernardi, L., Maletta, R., Bruni, A.C., Geroldi, D. Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia. Arch. Neurol. 2005, 62(11), 1734-1736.
166. Staniszewska, M., Leszek, J., Malyszczak, K., Gamian, A. Are advanced glycation end-products specific biomarkers for Alzheimer’s disease?Int. J. Geriatr. Psychiatry2005,20(9), 896-897.
167. Hernanz, A., De la Fuente, M., Navarro, M., Frank, A. Plasma aminothiol compounds, but not serum tumor necrosis factor receptor II and soluble receptor for advanced glycation end products, are related to the cognitive impairment in Alzheimer’s disease and mild cognitive impairment patients. Neuroimmunomodulation2007,14(3-4), 163-167.
168. Riviere, S., Birlouez-Aragon, I., Vellas, B. Plasma protein glycation in Alzheimer’s disease. Glycoconj. J. 1998, 15(10), 1039-1042.
169. Castellani, R., Smith, M.A., Richey, P.L., Perry, G. Gly-coxidation and oxidative stress in Parkinson disease and diffuse Lewy body disease. Brain Res. 1996, 737(1-2), 195-200.
170. Munch, G., Luth, H.J., Wong, A., Arendt, T., Hirsch, E., Ravid, R., Riederer, P Crosslinking of alpha-synuclein by advanced glycation endproducts—An early pathophysiological step in Lewy body formation?J. Chem. Neuro-anat. 2000,20(3-4), 253-257.
171. Thornalley, PJ. Glutathione-dependent detoxification of alpha-oxoaldehydes by the glyoxalase system: Involvement in disease mechanisms and antiproliferative activity of glyoxalase I inhibitors. Chem. Biol. Interact. 1998, 111-112,137-151.
172. Kikuchi, S., Shinpo, K., Ogata, A., Tsuji, S., Takeuchi, M., Makita, Z., Tashiro, K. Detection of N epsilon-(carboxymethyl)lysine (CML) and non-CML advanced glycation end-products in the anterior horn of amyotrophic lateral sclerosis spinal cord. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 2002, 3(2), 63-68.
173. Chou, S.M., Wang, H.S., Taniguchi, A., Bucala, R. Advanced glycation end products in neurofilament conglomeration of motoneurons in familial and sporadic amyotrophic lateral sclerosis. Mol. Med. 1998, 4(5), 324-332.
174. Shibata, N., Hirano, A., Hedley-Whyte, E.T., Dal Canto, M.C., Nagai, R., Uchida, K., Horiuchi, S., Kawaguchi, M., Yamamoto, T., Kobayashi, M. Selective formation of certain advanced glycation end products in spinal cord astrocytes of humans and mice with superoxide dismutase-1 mutation. Acta Neuropathol. 2002, 104(2),171-178.
175. Arai, K., Maguchi, S., Fujii, S., Ishibashi, H., Oikawa, K., Taniguchi, N. Glycation and inactivation of human Cu-Zn-superoxide dismutase. Identification of the in vitro glycated sites. J. Biol. Chem. 1987,262(35), 16969-16972.
176. Ilzecka, J. Serum-soluble receptor for advanced glycation end product levels in patients with amyotrophic lateral sclerosis. Acta Neurol. Scand. 2009,120(2), 119-122.
177. Sakaguchi, T., Yan, S.F., Yan, S.D., Belov, D., Rong, L.L., Sousa, M., Andrassy, M., Marso, S.P, Duda, S., Arnold, B., Liliensiek, B., Nawroth, P.P., Stern, D.M., Schmidt, A.M., Naka, Y. Central role of RAGE-dependent neointimal expansion in arterial restenosis. J. Clin. Invest. 2003, 111(7), 959-972.
178. Kaufmann, E., Boehm, B.O., Sussmuth, S.D., Kientsch-Engel, R., Sperfeld, A., Ludolph, A.C., Tumani, H. The advanced glycation end-product N epsilon-(carboxymethyl)lysine level is elevated in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Neurosci. Lett. 2004, 371(2-3), 226-229.
179. Barciszewski, J., Barciszewska, M.Z., Siboska, G., Rattan, S.I., Clark, B.F. Some unusual nucleic acid bases are products of hydroxyl radical oxidation of DNA and RNA. Mol. Biol. Rep. 1999,26(4), 231-238.
180. Yanagawa, H., Ogawa, Y., Ueno, M. Redox ribonucleo-sides. Isolation and characterization of 5-hydroxyuridine, 8-hydroxyguanosine, and 8-hydroxyadenosine from Torula yeast RNA. J. Biol. Chem. 1992, 267(19), 13320-13326.
181. Helbock, H.J., Beckman, K.B., Ames, B.N. 8-Hydroxydeoxyguanosine and 8-hydroxyguanine as biomarkers of oxidative DNA damage. Methods Enzymol. 1999,300,156-166.
182. Lovell, M.A., Markesbery, W.R. Oxidative damage in mild cognitive impairment and early Alzheimer’s disease. J. Neurosci. Res. 2007, 15(14), 3036-3040.
183. Nunomura, A., Chiba, S., Lippa, C.F., Cras, P, Kalaria, R. N., Takeda, A., Honda, K., Smith, M.A., Perry, G. Neuronal RNA oxidation is a prominent feature of familial Alzheimer’s disease. Neurobiol. Dis. 2004, 77(1), 108-113.
184. Nunomura, A., Perry, G., Pappolla, M.A., Friedland, R.P, Hirai, K., Chiba, S., Smith, M.A. Neuronal oxidative stress precedes amyloid-beta deposition in Down syndrome. J. Neuropathol. Exp. Neurol. 2000, 59(11), 1011-1017.
185. Nunomura, A., Perry, G., Aliev, G., Hirai, K., Takeda, A., Balraj, E.K., Jones, PK., Ghanbari, H., Wataya, T., Shimohama, S., Chiba, S., Atwood, C.S., Petersen, R.B., Smith, M.A. Oxidative damage is the earliest event in Alzheimer disease. J. Neuropathol. Exp. Neurol. 2001, 60(8), 759-767.
186. Lovell, M.A., Markesbery, W.R. Oxidatively modified RNA in mild cognitive impairment. Neurobiol. Dis. 2008, 29(2), 169-175.
187. Honda, K., Smith, M.A., Zhu, X., Baus, D., Merrick, W.C., Tartakoff, A.M., Hattier, T., Harris, PL., Siedlak, S.L., Fujioka, H., Liu, Q., Moreira, PI., Miller, F.P, Nunomura, A., Shimohama, S., Perry, G. Ribosomal RNA in Alzheimer disease is oxidized by bound redox-active iron. J. Biol. Chem. 2005, 280(22),20978-20986.
188. Abe, T., Tohgi, H., Isobe, C., Murata, T., Sato, C. Remarkable increase in the concentration of 8-hydroxyguanosine in cerebrospinal fluid from patients with Alzheimer’s disease. J. Neurosci. Res. 2002, 70(3), 447-450.
189. Abe, T., Isobe, C., Murata, T., Sato, C., Tohgi, H. Alteration of 8-hydroxyguanosine concentrations in the cerebrospinal fluid and serum from patients with Parkinson’s disease. Neurosci. Lett. 2003,336(2), 105-108.
190. Zhang, J., Perry, G., Smith, M.A., Robertson, D., Olson, S. J., Graham, D.G., Montine, T.J. Parkinson’s disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. Am. J. Pathol. 1999,154(5),1423-1429.
191. Chang, Y., Kong, Q., Shan, X., Tian, G., Ilieva, H., Cleveland, D.W., Rothstein, J.D., Borchelt, D.R., Wong, PC., Lin, C.L. Messenger RNA oxidation occurs early in disease pathogenesis and promotes motor neuron degeneration in ALS. PLoS ONE 2008, 3(8), e2849.
192. Kong, Q., Lin, C.L. Oxidative damage to RNA: Mechanisms, consequences, and diseases. Cell. Mol. Life Sci. 2010, 67(11), 1817-1829.
193. Wang, J., Xiong, S., Xie, C., Markesbery, W.R., Lovell, M. A. Increased oxidative damage in nuclear and mitochondrial DNA in Alzheimer’s disease. J. Neurochem. 2005, 93(4),953-962.
194. Gabbita, S.P., Lovell, M.A., Markesbery, W.R. Increased nuclear DNA oxidation in the brain in Alzheimer’s disease. J. Neurochem. 1998, 77(5), 2034-2040.
195. Migliore, L., Fontana, I., Trippi, F., Colognato, R., Coppede, F., Tognoni, G., Nucciarone, B., Siciliano, G. Oxidative DNA damage in peripheral leukocytes of mild cognitive impairment and AD patients. Neurobiol. Aging2005,26(5), 567-573.
196. Mecocci, P., Polidori, M.C., Ingegni, T., Cherubini, A., Chionne, F., Cecchetti, R., Senin, U. Oxidative damage to DNA in lymphocytes from AD patients. Neurology1998, 51(4), 1014-1017.
197. Kadioglu, E., Sardas, S., Aslan, S., Isik, E., Esat Karakaya, A. Detection of oxidative DNA damage in lymphocytes of patients with Alzheimer’s disease. Biomarkers2004, 9(2), 203-209.
198. Lovell, M.A., Gabbita, S.P, Markesbery, W.R. Increased DNA oxidation and decreased levels of repair products in Alzheimer’s disease ventricular CSF. J. Neurochem. 1999, 72(2), 771-776.
199. Mecocci, P., MacGarvey, U., Beal, M.F. Oxidative damage to mitochondrial DNA is increased in Alzheimer’s disease. Ann. Neurol. 1994,36(5), 747-751.
200. Wang, J., Markesbery, W.R., Lovell, M.A. Increased oxidative damage in nuclear and mitochondrial DNA in mild cognitive impairment. J. Neurochem. 2006, 96(3), 825-832.
201. Weissman, L., Jo, D.G., Sorensen, M.M., de Souza-Pinto, N. C., Markesbery, W.R., Mattson, M.P., Bohr, V.A. Defective DNA base excision repair in brain from individuals with Alzheimer’ s disease and amnestic mild cognitive impairment. Nucleic Acids Res. 2007, 35(16), 5545-5555.
202. Alam, Z.I., Jenner, A., Daniel, S.E., Lees, A.J., Cairns, N., Marsden, C.D., Jenner, P., Halliwell, B. Oxidative DNA damage in the Parkinsonian brain: An apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J. Neurochem. 1997, 69(3), 1196-1203.
203. Spencer, J.P, Jenner, A., Aruoma, O.I., Evans, PJ., Kaur, H., Dexter, D.T., Jenner, P., Lees, A.J., Marsden, D.C., Halliwell, B. Intense oxidative DNA damage promoted by L-dopa and its metabolites. Implications for neurodegenerative disease. FEBS Lett. 1994,353(3), 246-250.
204. Walkinshaw, G., Waters, C.M. Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA. Implications for the treatment of Parkinson’s disease. J. Clin. Invest. 1995, 95(6), 2458-2464.
205. Kikuchi, A., Takeda, A., Onodera, H., Kimpara, T., Hisanaga, K., Sato, N., Nunomura, A., Castellani, R.J., Perry, G., Smith, M.A., Itoyama, Y. Systemic increase of oxidative nucleic acid damage in Parkinson’s disease and multiple system atrophy. Neurobiol. Dis. 2002, 9(2), 244-248.
206. Sato, S., Mizuno, Y., Hattori, N. Urinary 8-hydroxydeoxyguanosine levels as a biomarker for progression of Parkinson disease. Neurology2005, 64(6), 1081-1083.
207. Fitzmaurice, PS., Shaw, I.C., Kleiner, H.E., Miller, R.T., Monks, T.J., Lau, S.S., Mitchell, J.D., Lynch, PG. Evidence for DNA damage in amyotrophic lateral sclerosis. Muscle Nerve1996,19(6), 797-798.
208. Murata, T., Ohtsuka, C., Terayama, Y. Increased mitochondrial oxidative damage and oxidative DNA damage contributes to the neurodegenerative process in sporadic amyotrophic lateral sclerosis. Free Radic. Res. 2008,42(3), 221-225.
209. Bogdanov, M., Brown, R.H., Matson, W., Smart, R., Hayden, D., O’Donnell, H., Flint Beal, M., Cudkowicz, M. Increased oxidative damage to DNA in ALS patients. Free Radic. Biol. Med. 2000,29(7), 652-658.
210. Mitsumoto, H., Santella, R.M., Liu, X., Bogdanov, M., Zipprich, J., Wu, H.C., Mahata, J., Kilty, M., Bednarz, K., Bell, D., Gordon, P.H., Hornig, M., Mehrazin, M., Naini, A., Flint Beal, M., Factor-Litvak, P. Oxidative stress biomarkers in sporadic ALS. Amyotroph. Lateral Scler. 2008, 9(3), 177-183.
211. Liu, D., Wen, J., Liu, J., Li, L. The roles of free radicals in amyotrophic lateral sclerosis: Reactive oxygen species and elevated oxidation of protein, DNA, and membrane phospholipids. FASEB J. 1999,13(15), 2318-2328.
212. Butterfield, D.A., Perluigi, M., Reed, T., Muharib, T., Hughes, C., Robinson, R., Sultana, R. Redox proteomics in selected neurodegenerative disorders: From its infancy to future applications. Antioxid. Redox Signal. 2012, 17(11), 1610-1655.